Artificial “dry” eye syndrome induced by long-term ophthalmic hypotensive therapy. Possibilities of medical correction
https://doi.org/10.25700/NJG.2020.01.08
Abstract
This article discusses the effect of prolonged instillations of ophthalmic antihypertensive drops on the ocular surface tissue, as one of the pathogenetic factors contributing to the occurrence of artifical or secondary dry eye syndrome (DES). It is known that the vast majority of antiglaucoma drops contain a preservative for the prevention of bacterial contamination of the vial: prolonging the shelf life of drops, the preservative prevents biodegradation and preserves the effectiveness of the drug, allowing you to use a convenient and safe bottle.The most common preservative, to date, is still benzalkonium chloride (BAK). But another thing is known: even at a minimum concentration, ВАК is able to have a cytotoxic effect on all structures of the eye surface. Even at a minimal concentration, BАК is capable of exerting a cytotoxic effect on all structures of the ocular surface. It is possible to reduce the toxic effects of the preservative on the ocular surface and stop the symptoms of DES using tear replacement therapy. The artificial tears replacement therapy proposed in the article is non-preservative, and the active substances that make up the preparations have proven effectiveness in the treatment and prevention of ocular surface xerosis.
About the Authors
V. P. Erichev
Scientific Research Institute of Eye Diseases
Russian Federation
Med.Sc.D., Professor, Head of Glaucoma Department
Russian Federation
Med.Sc.D., Professor, Head of Glaucoma Department
V. V. Averich
Scientific Research Institute of Eye Diseases
Russian Federation
M.D., Ph.D., Junior Science researcher of Refractive Department
Russian Federation
M.D., Ph.D., Junior Science researcher of Refractive Department
References
1. Erichev V.P., Ambartsumyan K.H. The preservatives and secondary dry eye syndrome in long-term topical open-angle glaucoma therapy. Glaucoma. 2011; 2:59-66. (In Russ.).
2. Maichuk Yu.F., Yani E.V. Study of effect of Ophtolique in the treatment of dry eye syndrome. Clinical ophthalmology. 2009; 10(1):33-35. (In Russ.).
3. Brzheskiy V.V. Glaukoma i sindrom «suhogo glaza» [Glaukoma and dry eye syndrome]. OOO «Company BORGES»; 2018. 228 p. (In Russ.).
4. Egorov E.A. Undesirable effects of hypotensive treatment. Clinical ophthalmology. 2007; 8(4):144–147. (In Russ.).
5. Farris R.L. Abnormalities of the tears and treatment of dry eye. The Cornea. Butterworth-Heinemann: Newton; 1998: 109-129.
6. Broadway D.C., Grierson I., O'Brien C. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994; 112(11):1437-1445.
7. Broadway D.C., Grierson I., O'Brien C. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112(11):1446-1454.
8. Sherwood M.B., Grierson I., Millar L. et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96(3):327-335.
9. Erichev V.P., Ambartsumyan K.H., Fedorov A.A. Clinical and morphological evidence of the effect of preservatives on the eye surface in primary open-angle glaucoma. Glaucoma. 2014; 13(4):13-22. (In Russ.).
10. Egorov E.A., Romanova T.B., Katz D.V. et al. Application of the solution Hyloparin-COMOD in ophthalmological practice (pilot study). Clinical ophthalmology. 2014; 4:207-212. (In Russ.).
11. Mastropasqua L., Agnifili L., Fasanella V., Curcio C., Ciabattoni C., Mastropasqua R., Ciancaglini M. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013; 91(5):397–405.
12. Arici M.K., Arici D.S., Topalkara A., Güler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exper Ophthalmol. 2000; 28(2)113–117.
13. Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23(5):490–496.
14. Egorova G.B., Erichev V.P., Subbot A.M., Fedorov A.A., Nesterova T.V., Gabashvili A.N., Averich V.V. Evaluation of Stillavit artificial tears potential in reducing the toxic effect of benzalkonium chloridecontaining hypotensive instillations on primary cell culture of the corneallimbus (experimental study). Glaucoma. 2017; 16(4):31-36. (In Russ.).
15. Yanchenko S.V., Eremenko A.I. Peculiarities of morphological status of conjunctiva in patients with POAG after prolonged usage of beta– blockers with conservative and with secondary «dry eye» syndrome. Clinical ophthalmology. 2008; 4:133-134. (In Russ.).
16. Rath A., Eichhorn M., Träger K., Paulsen F., Hampel U. In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells. Annals of Anatomy-Anatomischer Anzeiger. 2019; 222:129-138. doi:10.1016/j.aanat.2018.12.003
17. Aguayo B.A., Yeung J.Y., Chan C.C., Birt C.M. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metabolism Toxicology. 2016; 12(11):1279–1289.
18. Arita R., Itoh K., Maeda S., Maeda K., Furuta A., Tomidokoro M., Aihara S. Effects of long-term topical anti-glaucoma medications on meibomian glands. Graefe's Arch Clin Exper Ophthalmol. 2012; 250(8): 1181-1185. doi:10.1007/s00417-012-1943-6
19. Arita R., Iton K., Maeda S., Furuta A., Tomidokoro A., Aihara S. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea. 2012; 31 (11):1229-1234. doi:10.1097/ico.0b013e31823f8e7d
20. Muratova N.V. The diagnostic and treatment of dry eye syndrome in patients using b-blockers. Clinical ophthalmology. 2003; 1:4-6. (In Russ.).
21. Bonomi L., Zavarise G., Noya E., Michieletto S. Effects of timolol maleate on tear flow in human eyes. Graefe's Arch Clin Exper Ophthalmol. 1980; 213(1):19–22.
22. Bron A., Baudouin C., Denis P., Nordmann J.P., Renard J.P., Rouland J.F., Sellem E. Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy. J Franc d'Ophtalmol. 2008; 31(7):659–665.
23. Labbé A., Pauly A., Liang H., Brignole–Baudouin F., Martin C., Warnet J.M., Baudouin C. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium–1: an experimental study. J Ocular Pharmacol Ther. 2006; 22(4):267–278. doi:10.1089/jop.2006.22.267
24. Masschelein W.J. Chlorine dioxide. Ann Arbor Science Publishers. 1979; 172:177.
25. Mundorf T., Wilcox K.A., Ousler G.W., Welch D., Abelson M.B. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Advances in therapy. 2003; 20(6):329–336.
26. Lichter P.R., Musch D.C., Gillespie B.W., Guire K.E., Janz N.K., Wren P.A, Mills R.P. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108(11):1943–1953.
27. Rybakova E.G., Yegorova G.B., Kalinich N.I. Corneregel – new stimulator of reparative regeneration. Recipe. 2006; 48(4):126–128. (In Russ.).
28. Tkachenko N.V., Astakhov S.Yu. Experience of the use of Hyloparin in clinical practice. Ophthalmological Vedomosti. 2014; 7(4):53–62. (In Russ.).
29. Vita-POS. Tool lubricating eye care. Instruction for use. (In Russ.).
Review
For citations:
Erichev V.P., Averich V.V. Artificial “dry” eye syndrome induced by long-term ophthalmic hypotensive therapy. Possibilities of medical correction. National Journal glaucoma. 2020;19(1):55-60. (In Russ.) https://doi.org/10.25700/NJG.2020.01.08
Views:
883
Email this article 